Jinlu Tong1, Qing Zheng, Qinq Zheng1, Chenpeng Zhang2, Ryan Lo3, Jun Shen4, Zhihua Ran4. 1. 1] Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China [2] The first two authors contributed equally to this work. 2. Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 3. Department of Radiology, University of Chicago, Chicago, Illinois, USA. 4. Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China.
Abstract
OBJECTIVES: A systematic review and meta-analysis was conducted to provide an accurate estimate of the incidence rate of microscopic colitis (MC) and to assess the association between medication use and the risk of MC. METHODS: We searched Medline, Embase, and Institute for Scientific Information (ISI) Web of Science up to 26 September 2014 to identify published epidemiological studies of MC. The pooled incidence rate, female-to-male incidence rate ratio, age at diagnosis, prevalence, as well as odds ratios (ORs) of MC in association with medication use were calculated using a fixed-effects model or a random-effects model. RESULTS: Of the 1,972 citations retrieved, 25 studies were included. Pooled incidence rate of collagenous colitis (CC) was 4.14 (95% confidence interval (CI) 2.89-5.40) per 100,000 person-years and 4.85 (95% CI, 3.45-6.25) for lymphocytic colitis (LC). The female-to-male incidence rate ratios were 3.05 (95% CI 2.92-3.19) for CC and 1.92 (95% CI 1.53-2.31) for LC. The median age at diagnosis for CC was 64.9 (range, 57.03-72.78) years, similar to LC (median 62.18, range 53.99-70.38). Furthermore, the incidence rate of MC increased with rising age. A steadily increasing trend of incidence rate for both CC and LC was observed before 2000; however, the incidence rate since then has become stable in the United States, Sweden, and Spain. An increased risk of MC was associated with the use of proton pump inhibitors (PPIs) and selective serotonin reuptake inhibitors (SSRIs) (OR 2.68, 95% CI 1.73-4.17 and OR 2.41, 95% CI 1.64-3.53, respectively). CONCLUSIONS: MC is a common disease process. Female gender, increased age, and the use of PPIs and SSRIs are associated with a significantly increased risk of developing MC. Further work is needed to evaluate reported data from developing countries and to elucidate the biologic mechanisms behind the risk factors for MC.
OBJECTIVES: A systematic review and meta-analysis was conducted to provide an accurate estimate of the incidence rate of microscopic colitis (MC) and to assess the association between medication use and the risk of MC. METHODS: We searched Medline, Embase, and Institute for Scientific Information (ISI) Web of Science up to 26 September 2014 to identify published epidemiological studies of MC. The pooled incidence rate, female-to-male incidence rate ratio, age at diagnosis, prevalence, as well as odds ratios (ORs) of MC in association with medication use were calculated using a fixed-effects model or a random-effects model. RESULTS: Of the 1,972 citations retrieved, 25 studies were included. Pooled incidence rate of collagenous colitis (CC) was 4.14 (95% confidence interval (CI) 2.89-5.40) per 100,000 person-years and 4.85 (95% CI, 3.45-6.25) for lymphocytic colitis (LC). The female-to-male incidence rate ratios were 3.05 (95% CI 2.92-3.19) for CC and 1.92 (95% CI 1.53-2.31) for LC. The median age at diagnosis for CC was 64.9 (range, 57.03-72.78) years, similar to LC (median 62.18, range 53.99-70.38). Furthermore, the incidence rate of MC increased with rising age. A steadily increasing trend of incidence rate for both CC and LC was observed before 2000; however, the incidence rate since then has become stable in the United States, Sweden, and Spain. An increased risk of MC was associated with the use of proton pump inhibitors (PPIs) and selective serotonin reuptake inhibitors (SSRIs) (OR 2.68, 95% CI 1.73-4.17 and OR 2.41, 95% CI 1.64-3.53, respectively). CONCLUSIONS: MC is a common disease process. Female gender, increased age, and the use of PPIs and SSRIs are associated with a significantly increased risk of developing MC. Further work is needed to evaluate reported data from developing countries and to elucidate the biologic mechanisms behind the risk factors for MC.
Authors: Monina F Pascua; Prashant Kedia; Mark G Weiner; John Holmes; Jonas Ellenberg; James D Lewis Journal: Clin Med Insights Gastroenterol Date: 2010-05-18
Authors: D Keszthelyi; S V Jansen; G A Schouten; S de Kort; B Scholtes; L G J B Engels; A A M Masclee Journal: Aliment Pharmacol Ther Date: 2010-09-13 Impact factor: 8.171
Authors: Nicole M Gentile; Sahil Khanna; Edward V Loftus; Thomas C Smyrk; William J Tremaine; W Scott Harmsen; Alan R Zinsmeister; Patricia P Kammer; Darrell S Pardi Journal: Clin Gastroenterol Hepatol Date: 2013-10-09 Impact factor: 11.382
Authors: Ole K Bonderup; Morten Fenger-Grøn; Tatjana Wigh; Lars Pedersen; Gunnar L Nielsen Journal: Inflamm Bowel Dis Date: 2014-10 Impact factor: 5.325
Authors: A Münch; D Aust; J Bohr; O Bonderup; F Fernández Bañares; H Hjortswang; A Madisch; L K Munck; M Ström; C Tysk; S Miehlke Journal: J Crohns Colitis Date: 2012-06-15 Impact factor: 9.071
Authors: Gwen M C Masclee; Preciosa M Coloma; Ernst J Kuipers; Miriam C J M Sturkenboom Journal: Am J Gastroenterol Date: 2015-08 Impact factor: 10.864
Authors: Thomas De Corte; Emilie Janssens; Ann D'Hondt; Koen Thorrez; Joris Arts; Katrien Dejaegher; François D'Heygere; Annelies Holvoet; Bart van Besien; Luc Harlet; Harald Peeters; Wouter Van Moerkercke; Filip Baert Journal: United European Gastroenterol J Date: 2019-07-12 Impact factor: 4.623
Authors: Alexander Khoruts; Kevin M Rank; Krista M Newman; Kimberly Viskocil; Byron P Vaughn; Matthew J Hamilton; Michael J Sadowsky Journal: Clin Gastroenterol Hepatol Date: 2016-02-22 Impact factor: 11.382
Authors: Kelly C Cushing; Mari Mino-Kenudson; John Garber; Paul Lochhead; Hamed Khalili Journal: Am J Gastroenterol Date: 2018-04 Impact factor: 10.864